UK – MHRA approves UK’s first anti-PD-1 monoclonal antibody for treatment of aggressive form of lung cancer
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 20 June 2025, approved serplulimab (Hetronifly) to treat adults with extensive-stage small cell lung cancer (ES-SCLC), which has not previously been treated, and has spread...





